ALSO NOTED: Cancer-sniffing dog being cloned; Investment spurs Bioton shares; Genetic Chemistry wins $23M contract; Tioga touts

> The world's top cancer-sniffing canine has been cloned, and her owners are planning a pack of clones to join the hunt for canine cancer detection. Researchers have been testing dogs' ability to detect early-stage cancer cells in urine and breath. Report

> Shares of Poland's Bioton surged on the news that one of the country's richest men, Zygmunt Solorz-Zak, bought a 10 percent stake in the company worth $89 million. Report

> Genetic Chemistry has won a $22.8 million contract from the U.S. Army Research Office to develop novel compounds that act against bacterium that is classified as a Category B bioterror threat. Report

> Tioga Pharmaceuticals says that a recent Phase IIb study of its oral kappa opioid receptor agonist, asimadoline, produced statistically significant results in the treatment of Irritable Bowel Syndrome. Release

> Sunesis Pharmaceuticals has launched a Phase II trial of voreloxin (SNS-595), the company's lead anti-cancer therapeutic. Report

> The news that the FDA had put a 'clinical hold' on Geron's plans to launch the first U.S. clinical trial of a stem cell therapy is attracting considerable scrutiny from researchers. Geron report

> Twenty-five years after the discovery of the human immunodeficiency virus, top scientists from around the world gathered at the Pasteur Institute to mark major advances in the field and come to terms with some of the grim realities that now afflict their work. Report

> Perrigo has formed a joint development agreement with Cobrek Pharmaceuticals and taken a minority stake in the new drug company. Report

> Merck made a $58 million deal to settle claims of deceptive Vioxx advertising with a 29 attorneys general. Report

> Fresh on the heels of their DTC hearing, Congressmen John Dingell and Bart Stupak have issued letters to four top pharma execs--CEOs at Merck, Pfizer, Schering-Plough, and Johnson & Johnson--asking them to commit to honest-Abe advertising. DTC report

Special Report: The top 17 salaries in Big Pharma. List 

And Finally… The National Institutes of Health has created a new research program that is devoting itself to studying patients with mystery diseases. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.